Age-associated B cells predict impaired humoral immunity after COVID-19 vaccination in patients receiving immune checkpoint blockade
-
Published:2023-06-27
Issue:1
Volume:14
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Yam-Puc Juan CarlosORCID, Hosseini Zhaleh, Horner Emily C.ORCID, Gerber Pehuén Pereyra, Beristain-Covarrubias Nonantzin, Hughes Robert, Lulla Aleksei, Rust Maria, Boston Rebecca, Ali MagdaORCID, Fischer KatrinORCID, Simmons-Rosello Edward, O’Reilly MartinORCID, Robson Harry, Booth Lucy H., Kahanawita Lakmini, Correa-Noguera Andrea, Favara David, Ceron-Gutierrez Lourdes, Keller Baerbel, Craxton Andrew, Anderson Georgina S. F., Sun Xiao-Ming, Elmer Anne, Saunders Caroline, Bermperi Areti, Jose Sherly, Kingston Nathalie, Mulroney Thomas E., Piñon Lucia P. G., Chapman Michael A., Grigoriadou Sofia, MacFarlane Marion, Willis Anne E., Patil Kiran R., Spencer Sarah, Staples Emily, Warnatz KlausORCID, Buckland Matthew S.ORCID, Hollfelder FlorianORCID, Hyvönen MarkoORCID, Döffinger RainerORCID, Parkinson Christine, Lear Sara, Matheson Nicholas J.ORCID, Thaventhiran James E. D.ORCID,
Abstract
AbstractAge-associated B cells (ABC) accumulate with age and in individuals with different immunological disorders, including cancer patients treated with immune checkpoint blockade and those with inborn errors of immunity. Here, we investigate whether ABCs from different conditions are similar and how they impact the longitudinal level of the COVID-19 vaccine response. Single-cell RNA sequencing indicates that ABCs with distinct aetiologies have common transcriptional profiles and can be categorised according to their expression of immune genes, such as the autoimmune regulator (AIRE). Furthermore, higher baseline ABC frequency correlates with decreased levels of antigen-specific memory B cells and reduced neutralising capacity against SARS-CoV-2. ABCs express high levels of the inhibitory FcγRIIB receptor and are distinctive in their ability to bind immune complexes, which could contribute to diminish vaccine responses either directly, or indirectly via enhanced clearance of immune complexed-antigen. Expansion of ABCs may, therefore, serve as a biomarker identifying individuals at risk of suboptimal responses to vaccination.
Funder
RCUK | MRC | Medical Research Foundation Evelyn Trust RCUK | Medical Research Council
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference77 articles.
1. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021). 2. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). 3. Schmidt, A. L. et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann. Oncol. 33, 340–346 (2022). 4. Monin, L. et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 22, 765–778 (2021). 5. Goshen-Lago, T. et al. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 7, 1507–1513 (2021).
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|